4th International conference on phase 1 and early phase clinical trials

March 1-2, 2018 | Hyatt Regency Hong Kong, Tsim Sha Tsui, 18 Hanoi Road, Kowloon, Hong Kong

Overview

Opportunity to meet and interact with globally renowned speakers and experts.

Exchanging ideas on the latest trends on new drug development in various disease areas, in Asia and worldwide.

ICPOEP2018 is a truly global event in clinical research, bringing together professionals from academic institutions, healthcare organizations, pharmaceutical companies, CROs regulatory authorities and others in exchanging insight and wisdom on the latest trends on new drug development. This year, the highlights will be clinical pharmacology, neurology and oncology.

SUPPORT FROM NEW β INNOVATION FOR THE ORGANIZATION OF THIS CONFERENCE IS GRATEFULLY ACKNOWLEDGED

organizer

The University of Hong Kong Clinical Trials Centre (HKU-CTC) is celebrating its 20th anniversary!

HKU-CTC is an academic clinical research organization established under The University of Hong Kong (HKU) in 1998. It has been authorized as the central platform for management and coordination of clinical studies under HKU and its affiliated teaching hospital – Queen Mary Hospital.

Over the years, HKU-CTC has developed into a leading, full-service professional research organization offering one-stop clinical research solutions. HKU-CTC is devoted to partnering with clinical investigators, research organizations and the healthcare industry in advancing human healthcare by promoting, attracting and facilitating clinical studies of various natures, including:

  • investigator-initiated and industry-sponsored clinical studies;
  • interventional and non-interventional clinical studies;
  • clinical studies on various medicinal products such as small-molecule chemical drugs, biopharmaceuticals, medical devices, diagnostics, traditional/proprietary Chinese medicines, herbal medicines and health supplements;
  • phase 1 to 4 clinical trials;
  • clinical pharmacology and bioavailability/bioequivalence trials; and
  • clinical studies on clinical procedures and methods.

Learn more about HKU-CTC: www.hkuctc.com

organizing COMMITTEE

Chair
Professor Karen Lam

Chairman

Clinical Trials Centre,
The University of Hong Kong

Professor Yu-lung Lau

Chief Director

Clinical Trials Centre,
The University of Hong Kong

Professor Bernard Cheung

Medical Director

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Tommy Cheung

Deputy Medical Director
(Clinical Pharmacology)

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Joanne Chiu

Deputy Medical Director (Oncology)

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Thomas Yau

Clinical Associate Professor

Department of Medicine,
The University of Hong Kong

Mr. Henry Yau

Managing Director
Honorary Assistant Professor

Clinical Trials Centre,
The University of Hong Kong

  • Chair
    Professor Karen Lam

    Chairman

    Clinical Trials Centre,
    The University of Hong Kong

  • Professor Yu-lung Lau

    Chief Director

    Clinical Trials Centre,
    The University of Hong Kong

  • Professor Bernard Cheung

    Medical Director

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Tommy Cheung

    Deputy Medical Director
    (Clinical Pharmacology)

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Joanne Chiu

    Deputy Medical Director (Oncology)

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Thomas Yau

    Clinical Associate Professor

    Department of Medicine,
    The University of Hong Kong

  • Mr. Henry Yau

    Managing Director
    Honorary Assistant Professor

    Clinical Trials Centre,
    The University of Hong Kong

scientific COMMITTEE

Co-Chair
Professor Bernard Cheung

Medical Director

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Co-Chair
Professor Shu-Leong Ho

Henry G Leong Professor of Neurology

Department of Medicine,
The University of Hong Kong

Co-Chair
Dr. Thomas Yau

Clinical Associate Professor

Department of Medicine,
The University of Hong Kong

Dr. Koon-Ho Chan

Clinical Associate Professor

Department of Medicine,
The University of Hong Kong

Dr. Tommy Cheung

Deputy Medical Director
(Clinical Pharmacology)

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Joanne Chiu

Deputy Medical Director (Oncology)

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Roland Leung

Associate Consultant

Department of Medicine,
Queen Mary Hospital

Mr. Henry Yau

Managing Director
Honorary Assistant Professor

Clinical Trials Centre,
The University of Hong Kong

  • Co-Chair
    Professor Bernard Cheung

    Medical Director

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Co-Chair
    Professor Shu-Leong Ho

    Henry G Leong Professor of Neurology

    Department of Medicine,
    The University of Hong Kong

  • Co-Chair
    Dr. Thomas Yau

    Clinical Associate Professor

    Department of Medicine,
    The University of Hong Kong

  • Dr. Koon-Ho Chan

    Clinical Associate Professor

    Department of Medicine,
    The University of Hong Kong

  • Dr. Tommy Cheung

    Deputy Medical Director
    (Clinical Pharmacology)

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Joanne Chiu

    Deputy Medical Director (Oncology)

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Roland Leung

    Associate Consultant

    Department of Medicine,
    Queen Mary Hospital

  • Mr. Henry Yau

    Managing Director
    Honorary Assistant Professor

    Clinical Trials Centre,
    The University of Hong Kong

speakers

conference program

  • Day One: March 1, 2018 (Thursday)

  • Time Topics & Speakers
  • 09:15 – 10:00 Registration
  • 10:00 – 11:30 Session I: Breakthrough in Parkinson’s Disease Research

    Chair:

    Professor Bernard Cheung, Medical Director, Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China

    Professor Shu-Leong Ho, Henry G Leong Professor of Neurology, Department of Medicine, The University of Hong Kong, HKSAR, China

  • 10:00 – 10:30 Redefining Parkinson's Disease

    Professor Peter Jenner, Emeritus Professor of Pharmacology, Neurodegenerative Diseases Research Group, Faculty of Life Sciences and Medicine, King’s College London, UK

  • 10:30 – 11:00 Drug Development for Parkinson's Disease: A Half-Century of Progress and Challenges

    Professor Peter LeWitt, Professor of Neurology, Wayne State University School of Medicine / Director of Parkinson's Disease and Movement Disorders Program, Henry Ford Hospital, Michigan, USA

  • 11:00 – 11:30 Targeting the LRRK2 Protein Kinase for the Treatment of Parkinson’s Disease

    Professor Dario Alessi, Director of MRC Protein Phosphorylation & Ubiquitylation Unit, University of Dundee, UK

  • 11:30 – 13:00 Lunch
  • 13:00 – 15:00 Session II: Advancement in Stroke Therapies

    Chair:

    Dr. Koon-Ho Chan, Clinical Associate Professor, Department of Medicine, The University of Hong Kong, HKSAR, China

    Dr. Cornelia Man, Director, Clinical Projects and Development, New ß Innovation, HKSAR, China

  • 13:00 – 13:30 Understanding Stroke-Induced Heart Disease

    Dr. Luciano Sposato, Associate Professor of Department of Clinical Neurological Sciences / Director of Stroke, Dementia and Heart Disease Laboratory, Western University, London, Ontario, Canada

  • 13:30 – 14:00 Stroke Prevention in Atrial Fibrillation – Past, Present and Future

    Professor Raymond Cheung, Lee Man Chiu Professor in Neuroscience of Division of Neurology, Department of Medicine, The University of Hong Kong, HKSAR, China

  • 14:00 – 14:30 Human Genetic Investigation as a Pipeline for Drug Discovery for Cerebrovascular Disease

    Professor Jonathan Rosand, Professor of Neurology, Harvard Medical School / Managing Director of Neuroscience Institute, Massachusetts General Hospital and Associate Member of Broad Institute, Boston, USA

  • 14:30 – 15:00 Advances in Stroke Therapy through Multinational Clinical Trials

    Professor Chung-Yi Hsu, Chair Professor of Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan

  • 15:00 – 15:30 Coffee Break
  • 15:30 – 16:00 Opening Remarks:

    Professor Gabriel Leung, GBS, JP, Dean, LKS Faculty of Medicine, The University of Hong Kong, HKSAR, China

    Dr. Che-Chung Luk, Cluster Chief Executive, Hong Kong West Cluster, Hospital Authority, HKSAR, China

  • 16:00 – 16:45 Dr. Cheng Yu Tung Award Lecture in Drug Development

    Chair:

    Professor Karen Lam, Chairman, Clinical Trials Centre, The University of Hong Kong, HKSAR, China

    Professor Shu-Leong Ho, Henry G Leong Professor of Neurology, Department of Medicine, The University of Hong Kong, HKSAR, China

  • Gene Silencing Therapy for Neurodegenerative Disease

    Professor Don W. Cleveland, Head of Laboratory of Cell Biology, Ludwig Institute for Cancer Research / Distinguished Professor and Chair of Department of Cellular and Molecular Medicine, University of California San Diego, USA

  • 16:45 – 17:30 Panel Discussion: Opportunities and Challenges in Novel Drug Development

    Moderator:

    Professor Bernard Cheung, Medical Director, Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China

    Panelist:

    Professor Don W. Cleveland, University of California San Diego, USA
    Professor Lee M. Ellis, University of Texas MD Anderson Cancer Center, Houston, USA
    Dr. Mario Tanguay, Syneos Health, Montreal, Canada

  • Day Two: March 2, 2018 (Friday)

  • Time Topics & Speakers
  • 09:00 – 09:30 Registration
  • 09:30 – 11:00 Session III: International Trends of Early Drug Development

    Chair: 

    Mr. Henry Yau, Managing Director / Honorary Assistant Professor, Clinical Trials Centre, The University of Hong Kong, HKSAR, China

    Mr. Daniel Li, Associate Director Clinical Operations Asia Pacific, Gilead Sciences HK Limited, Hong Kong, HKSAR, China

  • 09:30 – 10:00 Trends in the Design and Conduct of First-in-Human Trials

    Dr. Mario Tanguay, Vice President of Strategic Development, Syneos Health, Montreal, Canada

  • 10:00 – 10:30 The Importance of Early Phase Clinical Pharmacology Study for Successful Implementation of MRCT ICH E17 Guidelines

    Professor Haiyan Li, Professor of Cardiology / Director of Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, China

  • 10:30 – 11:00 Quality Management for Phase 1 Clinical Trials

    Ms. Agnes Chan, Specialist, BioResearch Quality & Compliance (BRQC) Quality Management, Janssen Pharmaceutical Companies of Johnson & Johnson, Singapore

  • 11:00 – 11:30 Coffee Break
  • 11:30 – 12:30 Session IV: Challenges in Phase 1 and Healthy Volunteer Trials

    Chair:

    Dr. Creany Wong, Associate Director, Business & Project Intelligence / Honorary Assistant Professor, Clinical Trials Centre, The University of Hong Kong, HKSAR, China

    Dr. Selene Tam, Associate Director, Project Operations, Clinical Trials Centre, The University of Hong Kong, HKSAR, China 

  • 11:30 – 12:00 How to meet the CFDA requirements for Phase 1 Clinical Trials

    Dr. Tommy Cheung, Deputy Medical Director (Clinical Pharmacology) of Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China

  • 12:00 – 12:30 Ethics Review of a Phase 1 Clinical Research in a New Technology

    Dr. Xiuqin Wang, Director of Research Operating Office, Jiangsu Academy of Clinical and Translational Research / Chief Ethics Officer and Vice-Chair of Institutional Review Board, Jiangsu Province Hospital, Nanjing, China

  • 12:30 – 14:00 Lunch
  • 14:00 – 15:30 Session V: Advancement in Oncology Treatment Strategies (I)

    Chair: 

    Professor Ronnie Poon, Medical Director, Hong Kong Integrated Oncology Centre , HKSAR, China

    Dr. Roland Leung, Associate Consultant, Department of Medicine, Queen Mary Hospital, HKSAR, China

  • 14:00 – 14:30 Targeting Genomic Stability in Cancer: Dream or Reality

    Professor Tak-wah Mak, Director of the Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre / Senior Staff Scientist of Ontario Cancer Institute, University Health Network / University Professor of Departments of Medical Biophysics and Immunology, University of Toronto, Toronto, Canada

  • 14:30 – 15:00 Early Development of Immuno-oncology Drugs – Novel Targets, Technology Platforms, and Trial Designs

    Dr. Archie Tse, Executive Director of Clinical Research Oncology, Merck & Co., Inc., USA

  • 15:00 – 15:30 Evolution of Phase 1 Development in Oncology

    Dr. Jeffrey Jackson, Early Asset Development Lead of Integrated Oncology, Bristol-Myers Squibb, New Jersey, USA

  • 15:30 – 16:00 Coffee Break
  • 16:00 – 18:00 Session VI: Advancement in Oncology Treatment Strategies (II)

    Chair:

    Dr. Thomas Yau, Clinical Associate Professor, Department of Medicine, The University of Hong Kong, HKSAR, China

    Dr. Joanne Chiu, Deputy Medical Director (Oncology), Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China

  • 16:00 – 16:30 Hypoxia in Cancer and Immune Cells

    Dr. Carmen Chak-Lui Wong, Assistant Professor of Department of Pathology, The University of Hong Kong, HKSAR, China

  • 16:30 – 17:00 YQ23 as a Radio-sensitizer in a Mouse Xenograft Hepatoma Model

    Professor Pierce Chow, Professor and Course Director of Duke-NUS Medical School / Senior Consultant of Division of Surgical Oncology, National Cancer Center Singapore / Senior Consultant of Department of Hepatopancreatobiliary / Transplant Surgery, Singapore General Hospital, Singapore

  • 17:00 – 17:30 Immuno-Oncology Combinations in Clinical Development

    Professor Lillian Siu, Director of Phase I and Cancer Genomics Program / BMO Chair in Precision Genomics, Princess Margaret Cancer Centre, Toronto, Canada

  • 17:30 – 18:00 Unbiased Approaches to Identify New Targets and Combination Therapies in CRC

    Professor Lee M. Ellis, Professor of Surgery and Molecular & Cellular Biology, University of Texas MD Anderson Cancer Center, Houston, USA

  • 18:00 – 18:15 Summary and Closing Remarks

    Professor Yu-Lung Lau, Chief Director, Clinical Trials Centre, The University of Hong Kong, HKSAR, China

venue

Hyatt Regency HK,
Tsim Sha Tsui,
18 Hanoi Road,
Kowloon, HKSAR, China

Main Conference

Hyatt Regency HK, Tsim Sha Tsui
18 Hanoi Road, Kowloon, HKSAR, China

Past Events

icpoep2016

3rd International Conference on
Phase 1 and Early Phase Clinical Trials

Innovative Drug Development For The Future

Visit Website

icpoep2015

2nd International Conference on
Phase 1 and Early Phase Clinical Trials

New Drug for life Tomorrow - in Asia and Worldwide

Visit Website

icpoep2013

1st International Conference on
Phase 1 and Early Phase Clinical Trials

New Drug for life Tomorrow - in Asia and Worldwide

Visit Website
  • icpoep2016

    3rd International Conference on
    Phase 1 and Early Phase Clinical Trials

    Innovative Drug Development For The Future

    Visit Website
  • icpoep2015

    2nd International Conference on
    Phase 1 and Early Phase Clinical Trials

    New Drug for life Tomorrow - in Asia and Worldwide

    Visit Website
  • icpoep2013

    1st International Conference on
    Phase 1 and Early Phase Clinical Trials

    New Drug for life Tomorrow - in Asia and Worldwide

    Visit Website
Background Image

contact

For enquires, please contact the Conference Secretariat Tel: +852 3605-9679 or +852 2255-4665 Email: icpoep2018@hku.hk